INS and metabolic dysfunction-associated steatohepatitis: TZDs has been shown to improve insulin sensitivity and liver fat accumulation in preclinical animal models of NASH (Kalavalapalli et al., 2018; Tahara and Takasu, 2019) and to be an effective therapy in patients with NASH (Della Pepa et al., 2021; Panunzi et al., 2021).